PT998276E - Utilizacao de derivados de alcanoil carnitina para o tratamento de disturbios de defice de atencao com hiperactividade - Google Patents
Utilizacao de derivados de alcanoil carnitina para o tratamento de disturbios de defice de atencao com hiperactividadeInfo
- Publication number
- PT998276E PT998276E PT98932502T PT98932502T PT998276E PT 998276 E PT998276 E PT 998276E PT 98932502 T PT98932502 T PT 98932502T PT 98932502 T PT98932502 T PT 98932502T PT 998276 E PT998276 E PT 998276E
- Authority
- PT
- Portugal
- Prior art keywords
- treatment
- alcanoyl
- hyperactivity
- attack
- deficiency disorders
- Prior art date
Links
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical class C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 title 1
- 230000007812 deficiency Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000013403 hyperactivity Diseases 0.000 title 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract 1
- -1 alkanoyl L-carnitine Chemical compound 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/898,433 US5869528A (en) | 1997-07-22 | 1997-07-22 | Therapeutical method for the treatment of attention-deficit/hyperactive disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT998276E true PT998276E (pt) | 2005-06-30 |
Family
ID=25409451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT98932502T PT998276E (pt) | 1997-07-22 | 1998-07-08 | Utilizacao de derivados de alcanoil carnitina para o tratamento de disturbios de defice de atencao com hiperactividade |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5869528A (https=) |
| EP (1) | EP0998276B1 (https=) |
| JP (1) | JP4276779B2 (https=) |
| KR (1) | KR100530879B1 (https=) |
| AT (1) | ATE290376T1 (https=) |
| AU (1) | AU735697B2 (https=) |
| CA (1) | CA2297153C (https=) |
| DE (1) | DE69829290T2 (https=) |
| ES (1) | ES2237842T3 (https=) |
| NZ (1) | NZ501966A (https=) |
| PT (1) | PT998276E (https=) |
| WO (1) | WO1999004785A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994391A (en) * | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| DK0951909T4 (da) | 1998-03-19 | 2011-01-24 | Sigma Tau Ind Farmaceuti | Kombinationspræparat omfattende en L-carnitin eller en alkanoyl-L-carnitin, en glycosaminoglycan og/eller bestanddel deraf |
| US6204291B1 (en) | 1998-06-26 | 2001-03-20 | The Iams Company | Process for promoting weight loss in overweight dogs |
| US6630159B2 (en) * | 1999-02-23 | 2003-10-07 | The Procter & Gamble Company | Limiting weight gain of cats by feeding carbohydrate source that excludes rice |
| US7001618B1 (en) | 1999-07-09 | 2006-02-21 | The Iams Company | Nutritional composition for weight management |
| WO2001028554A1 (en) * | 1999-10-20 | 2001-04-26 | Thomas Jefferson University | Treatment of attention deficit disorder and impaired visual-spatial function with androgen |
| ITRM20010218A1 (it) * | 2001-04-23 | 2002-10-23 | Sigma Tau Healthscience Spa | Composizione per la prevenzione o il trattamento dei disturbi dell'apprendimento in bambini affetti da deficit dell'attenzione ed iperattivi |
| JP4812968B2 (ja) * | 2001-06-06 | 2011-11-09 | 太陽化学株式会社 | 注意欠陥多動性障害改善用組成物 |
| US20050232911A1 (en) * | 2004-04-19 | 2005-10-20 | Schreiber Brian D | Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| AU2016219070B2 (en) | 2015-02-13 | 2020-06-11 | Mars, Incorporated | Pet food feeding system |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4346107A (en) * | 1979-02-12 | 1982-08-24 | Claudio Cavazza | Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism |
-
1997
- 1997-07-22 US US08/898,433 patent/US5869528A/en not_active Expired - Lifetime
-
1998
- 1998-07-08 EP EP98932502A patent/EP0998276B1/en not_active Expired - Lifetime
- 1998-07-08 CA CA002297153A patent/CA2297153C/en not_active Expired - Fee Related
- 1998-07-08 AU AU82405/98A patent/AU735697B2/en not_active Ceased
- 1998-07-08 ES ES98932502T patent/ES2237842T3/es not_active Expired - Lifetime
- 1998-07-08 NZ NZ501966A patent/NZ501966A/en not_active IP Right Cessation
- 1998-07-08 PT PT98932502T patent/PT998276E/pt unknown
- 1998-07-08 KR KR10-2000-7000575A patent/KR100530879B1/ko not_active Expired - Fee Related
- 1998-07-08 DE DE69829290T patent/DE69829290T2/de not_active Expired - Lifetime
- 1998-07-08 AT AT98932502T patent/ATE290376T1/de active
- 1998-07-08 WO PCT/IT1998/000188 patent/WO1999004785A1/en not_active Ceased
- 1998-07-08 JP JP2000503842A patent/JP4276779B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US5869528A (en) | 1999-02-09 |
| HK1028546A1 (en) | 2001-02-23 |
| KR20010022008A (ko) | 2001-03-15 |
| JP4276779B2 (ja) | 2009-06-10 |
| CA2297153C (en) | 2007-07-03 |
| WO1999004785A1 (en) | 1999-02-04 |
| EP0998276B1 (en) | 2005-03-09 |
| AU8240598A (en) | 1999-02-16 |
| ATE290376T1 (de) | 2005-03-15 |
| AU735697B2 (en) | 2001-07-12 |
| ES2237842T3 (es) | 2005-08-01 |
| DE69829290D1 (de) | 2005-04-14 |
| CA2297153A1 (en) | 1999-02-04 |
| DE69829290T2 (de) | 2006-04-13 |
| NZ501966A (en) | 2001-12-21 |
| JP2001510800A (ja) | 2001-08-07 |
| KR100530879B1 (ko) | 2005-11-23 |
| EP0998276A1 (en) | 2000-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT998276E (pt) | Utilizacao de derivados de alcanoil carnitina para o tratamento de disturbios de defice de atencao com hiperactividade | |
| ATE245978T1 (de) | Zusammensetzungen enthaltend propionyl-l- carnitine und hydroxyzitronensäure oder pantothensäure | |
| PT934061E (pt) | Isobutilgaba e seus derivados para o tratamento da dor | |
| CA2282654A1 (en) | Use of cholinesterase inhibitors to treat attention deficit hyperactivity disorder | |
| BR9508245A (pt) | Método para inhibir metástase de cáncer por administração oral de pectina citrica modificada solúvel | |
| CA2344407A1 (en) | Method for the treatment of mania and bipolar disorder | |
| DE59608698D1 (de) | Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure | |
| NO975234L (no) | Fremgangsmåte for behandling av maniske og bipolare forstyrrelser | |
| BR9608938A (pt) | Derivados dse fenóxi piperazina para o tratamento de distúrbios do sistema de dopamina | |
| ES2141463T3 (es) | Medicamento conteniendo un derivado de la carnitina para el tratamiento de la arteriosclerosis obliterans. | |
| ATE277611T1 (de) | Zusammensetzung, l-carnitin oder alkanoyl l- carnitin und langkettige alkanole enthaltend | |
| BR9811643A (pt) | Suplementação quìmica de osso | |
| MX9703810A (es) | Medicamento que comprende un derivado de carnitinapara tratar la enfermedad de alzheimer en pacientes con inicio prematuro. | |
| CY2207B1 (en) | Pharmaceutical for the treatment f skin disorders | |
| BR9911585A (pt) | Compostos derivados a partir de uma alfa-d-xilose, método para a preparação e uso terapêutico | |
| IT1299069B1 (it) | Composizione farmaceutica per il trattamento della "sindrome dolorosa regionale cronica" ("chronic regional pain syndrome crps") | |
| PT854862E (pt) | Processo para a preparacao de um aminoacido activado | |
| BR9813020A (pt) | Utilização de derivados de ácido lisofosfatidìlico, compostos e drogas que contém esses compostos | |
| FR2760452B1 (fr) | Procede d'obtention d'enantiomeres d'acides alpha-amines et sels diastereoisomeriques intermediaires | |
| SI0998276T1 (en) | Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders | |
| BR9909878A (pt) | 10-canfosulfonato de paroxetina para tratamento de distúrbios do sistema nervoso central | |
| Relja et al. | Low dose clozapine improves dyskinesias in PD: A double blind study | |
| UA8280A (uk) | Спосіб лікування псоріазу | |
| ATE232196T1 (de) | Ammoniumsalze von phenoxy-isobuttersäure und diese enthaltende pharmazeutische formulierungen |